×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
APLT – applied therapeutics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
APLT
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/7
07:00 am
aplt
Applied Therapeutics Reports Third Quarter 2024 Financial Results
Medium
Report
Applied Therapeutics Reports Third Quarter 2024 Financial Results
11/5
07:00 am
aplt
Applied Therapeutics to Present at the 2024 UBS Global Healthcare Conference
Medium
Report
Applied Therapeutics to Present at the 2024 UBS Global Healthcare Conference
9/24
11:32 am
aplt
Is Applied Therapeutics (APLT) Stock Outpacing Its Medical Peers This Year? [Yahoo! Finance]
Medium
Report
Is Applied Therapeutics (APLT) Stock Outpacing Its Medical Peers This Year? [Yahoo! Finance]
9/23
02:14 pm
aplt
All You Need to Know About Applied Therapeutics (APLT) Rating Upgrade to Buy [Yahoo! Finance]
Low
Report
All You Need to Know About Applied Therapeutics (APLT) Rating Upgrade to Buy [Yahoo! Finance]
9/19
02:02 pm
aplt
APLT Stock Soars 69% on Positive Update on Galactosemia Drug NDA [Yahoo! Finance]
Low
Report
APLT Stock Soars 69% on Positive Update on Galactosemia Drug NDA [Yahoo! Finance]
9/19
12:14 pm
aplt
Applied Therapeutics, Inc. (NASDAQ: APLT) had its price target raised by analysts at Citigroup Inc. from $8.00 to $11.00. They now have a "buy" rating on the stock.
Medium
Report
Applied Therapeutics, Inc. (NASDAQ: APLT) had its price target raised by analysts at Citigroup Inc. from $8.00 to $11.00. They now have a "buy" rating on the stock.
9/19
09:33 am
aplt
Applied Therapeutics: AdCom Decision Takes Govorestat Approval A Step Closer [Seeking Alpha]
Low
Report
Applied Therapeutics: AdCom Decision Takes Govorestat Approval A Step Closer [Seeking Alpha]
9/19
09:21 am
aplt
Applied Therapeutics, Inc. (NASDAQ: APLT) had its price target raised by analysts at Leerink Partners from $11.00 to $14.00. They now have an "outperform" rating on the stock.
Low
Report
Applied Therapeutics, Inc. (NASDAQ: APLT) had its price target raised by analysts at Leerink Partners from $11.00 to $14.00. They now have an "outperform" rating on the stock.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/14
05:48 pm
aplt
Form SC 13G/A Applied Therapeutics, Filed by: Venrock Healthcare Capital Partners III, L.P.
Medium
Report
Form SC 13G/A Applied Therapeutics, Filed by: Venrock Healthcare Capital Partners III, L.P.
11/14
04:51 pm
aplt
Form SC 13G/A Applied Therapeutics, Filed by: PERCEPTIVE ADVISORS LLC
Medium
Report
Form SC 13G/A Applied Therapeutics, Filed by: PERCEPTIVE ADVISORS LLC
11/14
04:39 pm
aplt
Form SC 13G/A Applied Therapeutics, Filed by: Alyeska Investment Group, L.P.
Medium
Report
Form SC 13G/A Applied Therapeutics, Filed by: Alyeska Investment Group, L.P.
11/14
01:35 pm
aplt
Form SC 13G/A Applied Therapeutics, Filed by: JANUS HENDERSON GROUP PLC
Low
Report
Form SC 13G/A Applied Therapeutics, Filed by: JANUS HENDERSON GROUP PLC
11/14
12:01 pm
aplt
Form SC 13G/A Applied Therapeutics, Filed by: Vestal Point Capital, LP
Low
Report
Form SC 13G/A Applied Therapeutics, Filed by: Vestal Point Capital, LP
11/13
04:15 pm
aplt
Form SC 13G/A Applied Therapeutics, Filed by: ALEXANDRIA REAL ESTATE EQUITIES, INC.
Low
Report
Form SC 13G/A Applied Therapeutics, Filed by: ALEXANDRIA REAL ESTATE EQUITIES, INC.
11/8
02:21 pm
aplt
Form SC 13G Applied Therapeutics, Filed by: BlackRock, Inc.
Low
Report
Form SC 13G Applied Therapeutics, Filed by: BlackRock, Inc.
11/7
07:31 am
aplt
Form 10-Q Applied Therapeutics, For: Sep 30
Medium
Report
Form 10-Q Applied Therapeutics, For: Sep 30
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
1/8
Applied Therapeutics Announces Positive Topline Results of Pivotal Phase 2 ACTION-Galactosemia Study of AT-007 in Galactosemia Patients
41.5%
1/9 Applied Therapeutics (NASDAQ: APLT) had its price target raised by analysts at Citigroup Inc from $29.00 to $44.00. They now have a "buy" rating on the stock. 25.7%
5/13 Form 3 Applied Therapeutics For: May 13 Filed by: Funtleyder Leslie D. 16.9%
12/23 Form EFFECT Applied Therapeutics 14.4%
4/3 Form 3 Applied Therapeutics For: Apr 01 Filed by: Mahadevan Chids 9.9%
12/19 Form S-1/A Applied Therapeutics 7.3%
1/29 Form 4 Applied Therapeutics For: Jan 28 Filed by: MARCUS JOEL S 7.1%
3/13 Form 8-K Applied Therapeutics For: Mar 13 7.0%
3/3 Applied Therapeutics Appoints Adam Hansard as Chief Commercial Officer 6.5%
6/10 Applied Therapeutics (NASDAQ: APLT) is now covered by analysts at Robert W. Baird. They set an "outperform" rating on the stock. 6.5%
1/9 Applied Therapeutics (NASDAQ: APLT) had its price target raised by analysts at Citigroup Inc from $29.00 to $44.00. They now have a "buy" rating on the stock. 25.7%
5/13 Form 3 Applied Therapeutics For: May 13 Filed by: Funtleyder Leslie D. 16.9%
12/23 Form EFFECT Applied Therapeutics 14.4%
4/3 Form 3 Applied Therapeutics For: Apr 01 Filed by: Mahadevan Chids 9.9%
12/19 Form S-1/A Applied Therapeutics 7.3%
1/29 Form 4 Applied Therapeutics For: Jan 28 Filed by: MARCUS JOEL S 7.1%
3/13 Form 8-K Applied Therapeutics For: Mar 13 7.0%
3/3 Applied Therapeutics Appoints Adam Hansard as Chief Commercial Officer 6.5%
6/10 Applied Therapeutics (NASDAQ: APLT) is now covered by analysts at Robert W. Baird. They set an "outperform" rating on the stock. 6.5%
TOP News Decliners
3/16
Form POS AM Applied Therapeutics
-29.8%
3/10 Applied Therapeutics (NASDAQ: APLT) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -13.2%
3/11 Form 4 Applied Therapeutics For: Mar 09 Filed by: Hansard Adam -11.9%
4/21 Applied Therapeutics Announces Full Data and Scientific Presentations from the Pivotal Phase 2 ACTION-Galactosemia Trial -11.8%
6/21 Applied Therapeutics Reports First Quarter 2019 Financial Results -11.0%
12/5 Applied Therapeutics Announces Presentations Outlining the Design and Rationale for the ARISE-HF Pivotal Study of AT-001 for Treatment of Diabetic Cardiomyopathy at the 16th Annual Global Cardiovascular Clinical Trialist’s Forum (CVCT) -10.4%
3/31 Form 4 Applied Therapeutics For: Mar 27 Filed by: Alexandria Venture Investments, LLC -10.0%
3/5 Applied Therapeutics (APLT) Investor Presentation - Slideshow [Seeking Alpha] -9.3%
6/5 Form 4 Applied Therapeutics For: Jun 03 Filed by: Funtleyder Leslie D. -9.0%
8/8 Applied Therapeutics Reports AT-007 SAD Data from Healthy Volunteer Portion of Phase 1/2 ACTION-Galactosemia Study -8.1%
3/10 Applied Therapeutics (NASDAQ: APLT) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -13.2%
3/11 Form 4 Applied Therapeutics For: Mar 09 Filed by: Hansard Adam -11.9%
4/21 Applied Therapeutics Announces Full Data and Scientific Presentations from the Pivotal Phase 2 ACTION-Galactosemia Trial -11.8%
6/21 Applied Therapeutics Reports First Quarter 2019 Financial Results -11.0%
12/5 Applied Therapeutics Announces Presentations Outlining the Design and Rationale for the ARISE-HF Pivotal Study of AT-001 for Treatment of Diabetic Cardiomyopathy at the 16th Annual Global Cardiovascular Clinical Trialist’s Forum (CVCT) -10.4%
3/31 Form 4 Applied Therapeutics For: Mar 27 Filed by: Alexandria Venture Investments, LLC -10.0%
3/5 Applied Therapeutics (APLT) Investor Presentation - Slideshow [Seeking Alpha] -9.3%
6/5 Form 4 Applied Therapeutics For: Jun 03 Filed by: Funtleyder Leslie D. -9.0%
8/8 Applied Therapeutics Reports AT-007 SAD Data from Healthy Volunteer Portion of Phase 1/2 ACTION-Galactosemia Study -8.1%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: